Presentation is loading. Please wait.

Presentation is loading. Please wait.

Melanoma patient monocytes have altered expression of inflammatory and surface markers. Melanoma patient monocytes have altered expression of inflammatory.

Published bySteven Boyd Modified over 4 years ago

Similar presentations

Presentation on theme: "Melanoma patient monocytes have altered expression of inflammatory and surface markers. Melanoma patient monocytes have altered expression of inflammatory."— Presentation transcript:

1 Melanoma patient monocytes have altered expression of inflammatory and surface markers.
Melanoma patient monocytes have altered expression of inflammatory and surface markers. Cell surface markers on monocytes were measured by flow cytometry. Expression of cell surface markers on monocytes from malignant melanoma patients (MMP) and healthy volunteer controls (HV) for (A) costimulatory molecules CD80 and CD86 as a percentage of total monocytes; (B) MFI of TNFRII of total monocytes; (C) percentage of tissue factor positive of CD14+ monocytes; and (D) MFI of PD-L1/B7-H1 of total monocytes. A negative correlation is observed in patients with malignant melanoma when measuring surface expression of HLA-DR and PD-LI (E). Box and whisker plots: horizontal line, median; box, 25th and 75th percentiles; whiskers, min and max; **, P < 0.01. Rahul Chavan et al. Cancer Immunol Res 2014;2: ©2014 by American Association for Cancer Research

Download ppt "Melanoma patient monocytes have altered expression of inflammatory and surface markers. Melanoma patient monocytes have altered expression of inflammatory."

Similar presentations

A. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple.

A. a). d). c). f). b).e). g). Figure S1. NAT2 expression in lymphocytes and monocytes from a healthy volunteer. PBMC from a healthy volunteer were simple.
Fig. 2. Comparison of the Th1/Th2 ratio and the percentages of Th1 and Th2 cells between normal and allergic individuals. (A) The Th1/Th2 ratio observed.

Fig. 2. Comparison of the Th1/Th2 ratio and the percentages of Th1 and Th2 cells between normal and allergic individuals. (A) The Th1/Th2 ratio observed.
Expression of immune checkpoint molecules on leukocytes and tumor cells at baseline and in response to selinexor. Expression of immune checkpoint molecules.

Expression of immune checkpoint molecules on leukocytes and tumor cells at baseline and in response to selinexor. Expression of immune checkpoint molecules.
Melanoma donor (MD) NK cells are functionally impaired/exhausted.

Melanoma donor (MD) NK cells are functionally impaired/exhausted.
CD25 expression is associated with unfavorable clinical outcome.

CD25 expression is associated with unfavorable clinical outcome.
Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs
Nonclassical monocytes are specifically depleted following M-CSFR inhibition and these cells are highest in PD-L1 expression in blood of mice during therapy.

Nonclassical monocytes are specifically depleted following M-CSFR inhibition and these cells are highest in PD-L1 expression in blood of mice during therapy.
IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).
Graph (box plots) shows primary tumor volumes of oral and maxillary sinus (A) and pharyngeal (B) cancers categorized at T1–T4. Graph (box plots) shows.

Graph (box plots) shows primary tumor volumes of oral and maxillary sinus (A) and pharyngeal (B) cancers categorized at T1–T4. Graph (box plots) shows.
Depo-Provera altered the expression of cell surface markers associated with HIV susceptibility. Depo-Provera altered the expression of cell surface markers.

Depo-Provera altered the expression of cell surface markers associated with HIV susceptibility. Depo-Provera altered the expression of cell surface markers.
Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.
Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.
B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.
Tregs and APC subsets in TDLNs of patients with cervical cancer.

Tregs and APC subsets in TDLNs of patients with cervical cancer.
Leukocytes in human PDAC

Leukocytes in human PDAC
Postoperative changes in blood monocyte subsets.

Postoperative changes in blood monocyte subsets.
(A) HLA-E expression on the surface of CD14+ cells in patients with AS, HLA-B*2705, HLA-B*2709-positive and HLA-B27-negative HCs. Results are expressed.

(A) HLA-E expression on the surface of CD14+ cells in patients with AS, HLA-B*2705, HLA-B*2709-positive and HLA-B27-negative HCs. Results are expressed.
Quantification of MHC-I, β2m, and T-cell subsets.

Quantification of MHC-I, β2m, and T-cell subsets.
Differential expression of TRM markers by donor- and recipient-derived T cells with time. Differential expression of TRM markers by donor- and recipient-derived.

Differential expression of TRM markers by donor- and recipient-derived T cells with time. Differential expression of TRM markers by donor- and recipient-derived.
Figure 1 Flu immunization–induced changes in the proportions and absolute numbers of T cells and their relevant subpopulations Flu immunization–induced.

Figure 1 Flu immunization–induced changes in the proportions and absolute numbers of T cells and their relevant subpopulations Flu immunization–induced.

Similar presentations

Ads by Google